智克威得2019冠状病毒病疫苗 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "智克威得2019冠状病毒病疫苗" in Chinese language version.

refsWebsite

Global rank Chinese rank

27web.archive.org

1^st place

4clinicaltrials.gov

5,225^th place

4,888^th place

3nih.gov

4^th place

5^th place

3doi.org

2^nd place

23^rd place

3reuters.com

49^th place

81^st place

2scmp.com

362^nd place

236^th place

2worldcat.org

5^th place

12^th place

2chinanews.com

1,432^nd place

50^th place

1sina.com.cn

144^th place

3^rd place

1trackvaccines.org

low place

1covidvax.org

low place

1nst.com.my

1,512^th place

1,241^st place

1yicai.com

low place

482^nd place

1zj.gov.cn

low place

1,732^nd place

1elsevier.com

610^th place

388^th place

1szse.cn

low place

2,454^th place

1eastmoney.com

low place

960^th place

1cell.com

2,814^th place

3,256^th place

1gavi.org

low place

1nature.com

234^th place

227^th place

1zaobao.com.sg

2,796^th place

104^th place

1businessinsider.in

2,666^th place

4,654^th place

1eurasianet.org

3,649^th place

4,238^th place

1cnn.com

28^th place

71^st place

1nation.com.pk

2,180^th place

6,488^th place

1ft.com

210^th place

353^rd place

1xinhuanet.com

309^th place

19^th place

1kun.uz

7,232^nd place

low place

1hk01.com

379^th place

11^th place

1bbc.com

20^th place

41^st place

1nhc.gov.cn

low place

2,074^th place

bbc.com (Global: 20^th place; Chinese: 41^st place)

Uji klinis vaksin Anhui: Apa bedanya dengan Sinovac?. BBC News Indonesia. [2021-05-10]. （原始内容存档于2021-05-10）（印度尼西亚语）.

businessinsider.in (Global: 2,666^th place; Chinese: 4,654^th place)

Another Chinese Covid-19 vaccine enters late-stage human trials with a plan to produce 300 million doses annually. Business Insider. [2020-12-27]. （原始内容存档于2021-11-16）.

cell.com (Global: 2,814^th place; Chinese: 3,256^th place)

Dai, Lianpan; Zheng, Tianyi; Xu, Kun; Han, Yuxuan; Xu, Lili; Huang, Enqi; An, Yaling; Cheng, Yingjie; Li, Shihua. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS. Cell. 2020-08-06, 182 (3): 722–733.e11. ISSN 0092-8674. PMID 32645327. doi:10.1016/j.cell.2020.06.035 （英语）.

chinanews.com (Global: 1,432^nd place; Chinese: 50^th place)

cq.chinanews.com

李珩. 重组亚单位新冠疫苗在渝进入临床试验. 重庆日报. 2020-06-24 [2021-04-22]. （原始内容存档于2021-04-22）.

chinanews.com

孙自法. 中国研发全球首个获批使用新冠重组蛋白疫苗对新变种有效. 中国新闻网. 2021-03-25 [2021-04-22]. （原始内容存档于2021-04-25）.

clinicaltrials.gov (Global: 5,225^th place; Chinese: 4,888^th place)

Clinical trial number NCT04445194 for "Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine" at ClinicalTrials.gov
Clinical trial number NCT04466085 for "A Randomized, Blinded, Placebo-controlled Trial to Evaluate the Immunogenicity and Safety of a Recombinant New Coronavirus Vaccine (CHO Cell) With Different Doses and Different Immunization Procedures in Healthy People Aged 18 to 59 Years" at ClinicalTrials.gov
Clinical trial number NCT04550351 for "A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety and Tolerability of Recombinant New Coronavirus Vaccines (CHO Cells) in Healthy People Aged 60 Years and Above" at ClinicalTrials.gov
Clinical trial number NCT04646590 for "A Phase III Randomized, Double-blind, Placebo-controlled Clinical Trial in 18 Years of Age and Above to Determine the Safety and Efficacy of ZF2001, a Recombinant Novel Coronavirus Vaccine (CHO Cell) for Prevention of COVID-19" at ClinicalTrials.gov

cnn.com (Global: 28^th place; Chinese: 71^st place)

cnnespanol.cnn.com

Ecuador participará en ensayos de una vacuna china contra el covid-19. CNN. 2020-12-29 [2021-01-23]. （原始内容存档于2021-11-16）（西班牙语）.

covidvax.org (Global: low place; Chinese: low place)

COVID-19 Vaccine: RBD-Dimer by Anhui Zhifei Longcom Biopharma, Institute of Microbiology Chinese Academy of Sciences. covidvax.org. [2020-12-27]. （原始内容存档于2021-01-30）（英语）.

doi.org (Global: 2^nd place; Chinese: 23^rd place)

Yang, Shilong; Li, Yan; Dai, Lianpan; Wang, Jianfeng; He, Peng; Li, Changgui; Fang, Xin; Wang, Chenfei; Zhao, Xiang. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. The Lancet Infectious Diseases. 2021-03: S1473309921001274 [2021-06-11]. PMC 7990482 . PMID 33773111. doi:10.1016/S1473-3099(21)00127-4. （原始内容存档于2021-06-06）（英语）.
Dai, Lianpan; Zheng, Tianyi; Xu, Kun; Han, Yuxuan; Xu, Lili; Huang, Enqi; An, Yaling; Cheng, Yingjie; Li, Shihua. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS. Cell. 2020-08-06, 182 (3): 722–733.e11. ISSN 0092-8674. PMID 32645327. doi:10.1016/j.cell.2020.06.035 （英语）.
Dong, Yetian; Dai, Tong; Wei, Yujun; Zhang, Long; Zheng, Min; Zhou, Fangfang. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduction and Targeted Therapy. 2020-12, 5 (1): 237 [2021-05-09]. ISSN 2059-3635. PMC 7551521 . PMID 33051445. doi:10.1038/s41392-020-00352-y. （原始内容存档于2021-11-03）（英语）.

eastmoney.com (Global: low place; Chinese: 960^th place)

data.eastmoney.com

智飞生物:关于收到重组新型冠状病毒疫苗(CHO细胞)Ⅲ期临床试验关键性数据的提示性公告. 东方财富网. 2021-08-27 [2021-08-27]. （原始内容存档于2021-08-27）（中文）. 引用错误：带有name属性“:9”的<ref>标签用不同内容定义了多次

elsevier.com (Global: 610^th place; Chinese: 388^th place)

linkinghub.elsevier.com

Yang, Shilong; Li, Yan; Dai, Lianpan; Wang, Jianfeng; He, Peng; Li, Changgui; Fang, Xin; Wang, Chenfei; Zhao, Xiang. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. The Lancet Infectious Diseases. 2021-03: S1473309921001274 [2021-06-11]. PMC 7990482 . PMID 33773111. doi:10.1016/S1473-3099(21)00127-4. （原始内容存档于2021-06-06）（英语）.

eurasianet.org (Global: 3,649^th place; Chinese: 4,238^th place)

Uzbekistan poised to start trials on Chinese COVID-19 vaccine | Eurasianet. eurasianet.org. [2020-12-27]. （原始内容存档于2021-11-16）（英语）.

ft.com (Global: 210^th place; Chinese: 353^rd place)

Covid vaccine tracker: How do the leading jabs compare?. www.ft.com. 2020-12-23 [2020-12-27]. （原始内容存档于2021-01-26）（英国英语）.

gavi.org (Global: low place; Chinese: low place)

What are protein subunit vaccines and how could they be used against COVID-19?. www.gavi.org. [2020-12-27]. （原始内容存档于2021-08-17）（英语）.

hk01.com (Global: 379^th place; Chinese: 11^th place)

許祺安. 內地多地接種重組亞單位新冠疫苗需打3針注意事項一文看清. 香港01. 2021-04-18 [2021-08-30]. （原始内容存档于2021-08-06）（中文（香港））.

kun.uz (Global: 7,232^nd place; Chinese: low place)

uz, Kun. Uzbekistan receives 1 million doses of ZF-UZ-VAC 2001 vaccine. Kun.uz. [2021-03-28]. （原始内容存档于2021-11-16）（英语）.

nation.com.pk (Global: 2,180^th place; Chinese: 6,488^th place)

China's third vaccine enters Pakistan. The Nation. 2021-02-15 [2021-02-28] （英语）.

nature.com (Global: 234^th place; Chinese: 227^th place)

Dong, Yetian; Dai, Tong; Wei, Yujun; Zhang, Long; Zheng, Min; Zhou, Fangfang. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduction and Targeted Therapy. 2020-12, 5 (1): 237 [2021-05-09]. ISSN 2059-3635. PMC 7551521 . PMID 33051445. doi:10.1038/s41392-020-00352-y. （原始内容存档于2021-11-03）（英语）.

nhc.gov.cn (Global: low place; Chinese: 2,074^th place)

关于印发新冠病毒疫苗第二剂次加强免疫接种实施方案的通知. 中华人民共和国国家卫生健康委员会. 2022-12-14 [2022-12-14].

nih.gov (Global: 4^th place; Chinese: 5^th place)

ncbi.nlm.nih.gov

Yang, Shilong; Li, Yan; Dai, Lianpan; Wang, Jianfeng; He, Peng; Li, Changgui; Fang, Xin; Wang, Chenfei; Zhao, Xiang. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. The Lancet Infectious Diseases. 2021-03: S1473309921001274 [2021-06-11]. PMC 7990482 . PMID 33773111. doi:10.1016/S1473-3099(21)00127-4. （原始内容存档于2021-06-06）（英语）.
Dai, Lianpan; Zheng, Tianyi; Xu, Kun; Han, Yuxuan; Xu, Lili; Huang, Enqi; An, Yaling; Cheng, Yingjie; Li, Shihua. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS. Cell. 2020-08-06, 182 (3): 722–733.e11. ISSN 0092-8674. PMID 32645327. doi:10.1016/j.cell.2020.06.035 （英语）.
Dong, Yetian; Dai, Tong; Wei, Yujun; Zhang, Long; Zheng, Min; Zhou, Fangfang. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduction and Targeted Therapy. 2020-12, 5 (1): 237 [2021-05-09]. ISSN 2059-3635. PMC 7551521 . PMID 33051445. doi:10.1038/s41392-020-00352-y. （原始内容存档于2021-11-03）（英语）.

nst.com.my (Global: 1,512^th place; Chinese: 1,241^st place)

Ying TP. MYEG to conduct phase 3 clinical trial for China's Covid-19 vaccine in Msia | New Straits Times. NST Online. 2020-12-07 [2020-12-27]. （原始内容存档于2021-01-13）（英语）.

reuters.com (Global: 49^th place; Chinese: 81^st place)

Reuters Staff. Uzbekistan to carry out late-stage trial of Chinese COVID-19 vaccine candidate. Reuters. 2020-11-11 [2020-12-27]. （原始内容存档于2021-12-04）（英语）.
Liu, Roxanne. Sinopharm's COVID-19 vaccine remained active against S.Africa variant, effect reduced - lab study. Reuters. 2021-02-03 [2021-03-29]. （原始内容存档于2021-12-22）（英语）.
Mamatkulov, Mukhammadsharif. Uzbekistan approves Chinese-developed COVID-19 vaccine. Reuters. 2021-03-01 [2021-03-02]. （原始内容存档于2021-11-16）（英语）.

scmp.com (Global: 362^nd place; Chinese: 236^th place)

Fifth Chinese Covid-19 vaccine candidate ready to enter phase 3 trials. South China Morning Post. 2020-11-20 [2020-12-27]. （原始内容存档于2021-01-25）（英语）.
China’s production bottleneck ‘could be eased with latest Covid-19 vaccine’. South China Morning Post. 2021-03-17 [2021-03-18]. （原始内容存档于2021-10-09）（英语）.

sina.com.cn (Global: 144^th place; Chinese: 3^rd place)

finance.sina.com.cn

智飞生物业绩看上去很美，但撑得起3000亿市值吗？. 界面新闻. 2021-04-20 [2021-04-20]. （原始内容存档于2021-04-20）.

szse.cn (Global: low place; Chinese: 2,454^th place)

disc.static.szse.cn

智飞生物. 关于收到重组新型冠状病毒疫苗（CHO细胞）Ⅲ期临床试验关键性数据的提示性公告 (PDF). 2021-08-27 [2021-08-27]. （原始内容存档 (PDF)于2021-08-27）（中文）.

trackvaccines.org (Global: low place; Chinese: low place)

covid19.trackvaccines.org

Anhui Zhifei Longcom: RBD-Dimer – COVID19 Vaccine Tracker. covid19.trackvaccines.org. [2020-12-27]. （原始内容存档于2021-01-03）.

web.archive.org (Global: 1^st place; Chinese: 1^st place)

智飞生物业绩看上去很美，但撑得起3000亿市值吗？. 界面新闻. 2021-04-20 [2021-04-20]. （原始内容存档于2021-04-20）.
Anhui Zhifei Longcom: RBD-Dimer – COVID19 Vaccine Tracker. covid19.trackvaccines.org. [2020-12-27]. （原始内容存档于2021-01-03）.
COVID-19 Vaccine: RBD-Dimer by Anhui Zhifei Longcom Biopharma, Institute of Microbiology Chinese Academy of Sciences. covidvax.org. [2020-12-27]. （原始内容存档于2021-01-30）（英语）.
Fifth Chinese Covid-19 vaccine candidate ready to enter phase 3 trials. South China Morning Post. 2020-11-20 [2020-12-27]. （原始内容存档于2021-01-25）（英语）.
Ying TP. MYEG to conduct phase 3 clinical trial for China's Covid-19 vaccine in Msia | New Straits Times. NST Online. 2020-12-07 [2020-12-27]. （原始内容存档于2021-01-13）（英语）.
李珩. 重组亚单位新冠疫苗在渝进入临床试验. 重庆日报. 2020-06-24 [2021-04-22]. （原始内容存档于2021-04-22）.
钱童心. 高福团队研制全球首个重组新冠疫苗获中国紧急使用批准. 第一财经. 2021-03-16 [2021-04-22]. （原始内容存档于2021-04-22）.
China’s production bottleneck ‘could be eased with latest Covid-19 vaccine’. South China Morning Post. 2021-03-17 [2021-03-18]. （原始内容存档于2021-10-09）（英语）.
浙江省人民政府. 浙江省新冠肺炎疫情防控工作新闻发布会（第七十一场）. [2021-07-05]. （原始内容存档于2021-05-13）.
Yang, Shilong; Li, Yan; Dai, Lianpan; Wang, Jianfeng; He, Peng; Li, Changgui; Fang, Xin; Wang, Chenfei; Zhao, Xiang. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. The Lancet Infectious Diseases. 2021-03: S1473309921001274 [2021-06-11]. PMC 7990482 . PMID 33773111. doi:10.1016/S1473-3099(21)00127-4. （原始内容存档于2021-06-06）（英语）.
智飞生物. 关于收到重组新型冠状病毒疫苗（CHO细胞）Ⅲ期临床试验关键性数据的提示性公告 (PDF). 2021-08-27 [2021-08-27]. （原始内容存档 (PDF)于2021-08-27）（中文）.
智飞生物:关于收到重组新型冠状病毒疫苗(CHO细胞)Ⅲ期临床试验关键性数据的提示性公告. 东方财富网. 2021-08-27 [2021-08-27]. （原始内容存档于2021-08-27）（中文）. 引用错误：带有name属性“:9”的<ref>标签用不同内容定义了多次
What are protein subunit vaccines and how could they be used against COVID-19?. www.gavi.org. [2020-12-27]. （原始内容存档于2021-08-17）（英语）.
Dong, Yetian; Dai, Tong; Wei, Yujun; Zhang, Long; Zheng, Min; Zhou, Fangfang. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduction and Targeted Therapy. 2020-12, 5 (1): 237 [2021-05-09]. ISSN 2059-3635. PMC 7551521 . PMID 33051445. doi:10.1038/s41392-020-00352-y. （原始内容存档于2021-11-03）（英语）.
智飞生物冠病疫苗临床结果显示有效率达97%. 联合早报. 2021-03-26 [2021-04-03]. （原始内容存档于2021-04-21）（中文（简体））.
Another Chinese Covid-19 vaccine enters late-stage human trials with a plan to produce 300 million doses annually. Business Insider. [2020-12-27]. （原始内容存档于2021-11-16）.
Reuters Staff. Uzbekistan to carry out late-stage trial of Chinese COVID-19 vaccine candidate. Reuters. 2020-11-11 [2020-12-27]. （原始内容存档于2021-12-04）（英语）.
Uzbekistan poised to start trials on Chinese COVID-19 vaccine | Eurasianet. eurasianet.org. [2020-12-27]. （原始内容存档于2021-11-16）（英语）.
Ecuador participará en ensayos de una vacuna china contra el covid-19. CNN. 2020-12-29 [2021-01-23]. （原始内容存档于2021-11-16）（西班牙语）.
Covid vaccine tracker: How do the leading jabs compare?. www.ft.com. 2020-12-23 [2020-12-27]. （原始内容存档于2021-01-26）（英国英语）.
Liu, Roxanne. Sinopharm's COVID-19 vaccine remained active against S.Africa variant, effect reduced - lab study. Reuters. 2021-02-03 [2021-03-29]. （原始内容存档于2021-12-22）（英语）.
孙自法. 中国研发全球首个获批使用新冠重组蛋白疫苗对新变种有效. 中国新闻网. 2021-03-25 [2021-04-22]. （原始内容存档于2021-04-25）.
Mamatkulov, Mukhammadsharif. Uzbekistan approves Chinese-developed COVID-19 vaccine. Reuters. 2021-03-01 [2021-03-02]. （原始内容存档于2021-11-16）（英语）.
蔡国栋. 乌兹别克斯坦批准紧急使用中国一款新冠疫苗. 新华网. 2021-03-02 [2021-04-22]. （原始内容存档于2021-03-03）.
uz, Kun. Uzbekistan receives 1 million doses of ZF-UZ-VAC 2001 vaccine. Kun.uz. [2021-03-28]. （原始内容存档于2021-11-16）（英语）.
許祺安. 內地多地接種重組亞單位新冠疫苗需打3針注意事項一文看清. 香港01. 2021-04-18 [2021-08-30]. （原始内容存档于2021-08-06）（中文（香港））.
Uji klinis vaksin Anhui: Apa bedanya dengan Sinovac?. BBC News Indonesia. [2021-05-10]. （原始内容存档于2021-05-10）（印度尼西亚语）.

worldcat.org (Global: 5^th place; Chinese: 12^th place)

Dai, Lianpan; Zheng, Tianyi; Xu, Kun; Han, Yuxuan; Xu, Lili; Huang, Enqi; An, Yaling; Cheng, Yingjie; Li, Shihua. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS. Cell. 2020-08-06, 182 (3): 722–733.e11. ISSN 0092-8674. PMID 32645327. doi:10.1016/j.cell.2020.06.035 （英语）.
Dong, Yetian; Dai, Tong; Wei, Yujun; Zhang, Long; Zheng, Min; Zhou, Fangfang. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduction and Targeted Therapy. 2020-12, 5 (1): 237 [2021-05-09]. ISSN 2059-3635. PMC 7551521 . PMID 33051445. doi:10.1038/s41392-020-00352-y. （原始内容存档于2021-11-03）（英语）.

xinhuanet.com (Global: 309^th place; Chinese: 19^th place)

蔡国栋. 乌兹别克斯坦批准紧急使用中国一款新冠疫苗. 新华网. 2021-03-02 [2021-04-22]. （原始内容存档于2021-03-03）.

yicai.com (Global: low place; Chinese: 482^nd place)

钱童心. 高福团队研制全球首个重组新冠疫苗获中国紧急使用批准. 第一财经. 2021-03-16 [2021-04-22]. （原始内容存档于2021-04-22）.

zaobao.com.sg (Global: 2,796^th place; Chinese: 104^th place)

智飞生物冠病疫苗临床结果显示有效率达97%. 联合早报. 2021-03-26 [2021-04-03]. （原始内容存档于2021-04-21）（中文（简体））.

zj.gov.cn (Global: low place; Chinese: 1,732^nd place)

浙江省人民政府. 浙江省新冠肺炎疫情防控工作新闻发布会（第七十一场）. [2021-07-05]. （原始内容存档于2021-05-13）.

智克威得2019冠状病毒病疫苗 (Chinese Wikipedia)

bbc.com (Global: 20th place; Chinese: 41st place)

businessinsider.in (Global: 2,666th place; Chinese: 4,654th place)

cell.com (Global: 2,814th place; Chinese: 3,256th place)

chinanews.com (Global: 1,432nd place; Chinese: 50th place)

cq.chinanews.com

chinanews.com

clinicaltrials.gov (Global: 5,225th place; Chinese: 4,888th place)

cnn.com (Global: 28th place; Chinese: 71st place)

cnnespanol.cnn.com

covidvax.org (Global: low place; Chinese: low place)

doi.org (Global: 2nd place; Chinese: 23rd place)

eastmoney.com (Global: low place; Chinese: 960th place)

data.eastmoney.com

elsevier.com (Global: 610th place; Chinese: 388th place)

linkinghub.elsevier.com

eurasianet.org (Global: 3,649th place; Chinese: 4,238th place)

ft.com (Global: 210th place; Chinese: 353rd place)

gavi.org (Global: low place; Chinese: low place)

hk01.com (Global: 379th place; Chinese: 11th place)

kun.uz (Global: 7,232nd place; Chinese: low place)

nation.com.pk (Global: 2,180th place; Chinese: 6,488th place)

nature.com (Global: 234th place; Chinese: 227th place)

nhc.gov.cn (Global: low place; Chinese: 2,074th place)

nih.gov (Global: 4th place; Chinese: 5th place)

ncbi.nlm.nih.gov

nst.com.my (Global: 1,512th place; Chinese: 1,241st place)

reuters.com (Global: 49th place; Chinese: 81st place)

scmp.com (Global: 362nd place; Chinese: 236th place)

sina.com.cn (Global: 144th place; Chinese: 3rd place)

finance.sina.com.cn

szse.cn (Global: low place; Chinese: 2,454th place)

disc.static.szse.cn

trackvaccines.org (Global: low place; Chinese: low place)

covid19.trackvaccines.org

web.archive.org (Global: 1st place; Chinese: 1st place)

worldcat.org (Global: 5th place; Chinese: 12th place)

xinhuanet.com (Global: 309th place; Chinese: 19th place)

yicai.com (Global: low place; Chinese: 482nd place)

zaobao.com.sg (Global: 2,796th place; Chinese: 104th place)

zj.gov.cn (Global: low place; Chinese: 1,732nd place)

bbc.com (Global: 20^th place; Chinese: 41^st place)

businessinsider.in (Global: 2,666^th place; Chinese: 4,654^th place)

cell.com (Global: 2,814^th place; Chinese: 3,256^th place)

chinanews.com (Global: 1,432^nd place; Chinese: 50^th place)

clinicaltrials.gov (Global: 5,225^th place; Chinese: 4,888^th place)

cnn.com (Global: 28^th place; Chinese: 71^st place)

doi.org (Global: 2^nd place; Chinese: 23^rd place)

eastmoney.com (Global: low place; Chinese: 960^th place)

elsevier.com (Global: 610^th place; Chinese: 388^th place)

eurasianet.org (Global: 3,649^th place; Chinese: 4,238^th place)

ft.com (Global: 210^th place; Chinese: 353^rd place)

hk01.com (Global: 379^th place; Chinese: 11^th place)

kun.uz (Global: 7,232^nd place; Chinese: low place)

nation.com.pk (Global: 2,180^th place; Chinese: 6,488^th place)

nature.com (Global: 234^th place; Chinese: 227^th place)

nhc.gov.cn (Global: low place; Chinese: 2,074^th place)

nih.gov (Global: 4^th place; Chinese: 5^th place)

nst.com.my (Global: 1,512^th place; Chinese: 1,241^st place)

reuters.com (Global: 49^th place; Chinese: 81^st place)

scmp.com (Global: 362^nd place; Chinese: 236^th place)

sina.com.cn (Global: 144^th place; Chinese: 3^rd place)

szse.cn (Global: low place; Chinese: 2,454^th place)

web.archive.org (Global: 1^st place; Chinese: 1^st place)

worldcat.org (Global: 5^th place; Chinese: 12^th place)

xinhuanet.com (Global: 309^th place; Chinese: 19^th place)

yicai.com (Global: low place; Chinese: 482^nd place)

zaobao.com.sg (Global: 2,796^th place; Chinese: 104^th place)

zj.gov.cn (Global: low place; Chinese: 1,732^nd place)